Diabetes company Gloco has partnered with insulin dosing app Hedia.

Diabetes management company Gloco is partnering with Copenhagen-based Hedia to integrate its app into Gloco’s remote control platform. Hedia’s diabetes assistant allows patients to enter their blood glucose, food and activity levels, and provides bolus insulin recommendations. Under the partnership, the app will integrate with Gloco’s platform, which allows patients to share diabetes information with their providers, including blood glucose, insulin levels, food and carbohydrates, exercise, blood pressure and weight. In the EU, patients can use the app with a connected insulin pen. Gloco says using the functionality will give providers more insight into their patients’ insulin regimens. The companies expect to begin integration in Europe in the fourth quarter of this year and the first quarter of 2024. “We are excited to partner with Hedia to bring this algorithm-based innovation to diabetes patients and their healthcare teams for personalized healthcare,” Gloco CEO Russ Johansen said in a statement. “The strong clinical data supporting Hedia’s effectiveness show that it can be a good option for patients who cannot access insulin pumps. This partnership shows how to provide people with diabetes with better tools to manage their condition and improve health outcomes, such as blood glucose stability. Lilly has announced mergers with Sanofi, Novo Nordisk and Japanese medical device company Terumo. announced the acquisition. In March of last year, Gloco acquired another diabetes platform, Paris-based DIABNEXT. Evelyn Gallego will provide more details in the HIMSS23 session, “Health Equity Data: Improving Maternal Health Outcomes Through Action.” For Wednesday, April 19, 2:30 p.m. – 3:30 PM CT Booked at South Building, Level 1, S105A.

Leave a Reply

Your email address will not be published. Required fields are marked *